MedUni Vienna: "Nature Calendar" app to include allergenic plants
MedUni Vienna's pollen service complements Geosphere Austria's citizen science project
Biomay Offers Lipid-Nanoparticle Formulation Services for RNA Pharmaceuticals
Biomay today announced to offer GMP services for lipid-based nanoparticles (LNPs). With this, the company has completed…
MedUni Vienna: New treatment option for psoriasis discovered
Psoriasis is one of the most common chronic inflammatory skin diseases, affecting around 250,000 people in Austria.…
Hanke/Faßmann: AITHYRA Institut startet in der Marxbox in Wien
Wo künstliche Intelligenz (KI) in der Biomedizin zukünftig zu Hause ist
Valneva Receives EMA’s Positive CHMP Opinion for Adolescent Label Extension for Chikungunya Vaccine IXCHIQ®
If granted, IXCHIQ® will become the first vaccine against the chikungunya virus (CHIKV) available in the EU for…
Boehringer Ingelheim: Chronische Nierenerkrankung: innerhalb der Herz-Nieren- und Stoffwechsel-Erkrankungen lange still und unentdeckt
- Herz-Kreislauf-, Nieren- und Stoffwechselerkrankungen zählen zu den häufigsten Todesursachen weltweit.[1]
-…
FH Campus Wien: Neue MINT-Masterstudiengänge ab dem Wintersemester 2025/26
Die FH Campus Wien als größte Fachhochschule Österreichs baut ihr Studienangebot weiterhin kontinuierlich aus. Mit dem…
University Hospital Vienna/MedUni Vienna once again among the top hospitals worldwide
The University Hospital Vienna and the university departments operated jointly with MedUni Vienna have been ranked 27th…
vetmeduni Vienna: Anthrax: a lurking threat to humans and animals
An interdisciplinary team of researchers from the University of Veterinary Medicine Vienna, in collaboration with the…
L&R acquires teledermatology startup OnlineDoctor
This is the first acquisition of a digital health start-up in the company's history. OnlineDoctor is the market leader…
Pharmig: EU-Projekt soll Vernetzung bei seltenen Erkrankungen stärken
Europäische Referenznetzwerke müssen künftig stärker in nationale Gesundheitssysteme eingebunden werden, um die…
BlueSky Immunotherapies Reaches Milestone with delNS Viral Vector for OPSCC Treatment
- BlueSky Immunotherapies Reaches Milestone with delNS Viral Vector for OPSCC Treatment
- Innovative Approach Shows…